{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:29:04Z","timestamp":1792409344984,"version":"4.4.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vitiligo is a chronic autoimmune disease affecting melanocytes, resulting in skin depigmentation. Patients with vitiligo often have reduced quality of life and comorbid autoimmune conditions and have reported a lack of available treatments for their vitiligo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The Vitiligo and Life Impact Among International Communities (VALIANT) study is the first global survey to explore the natural history and management of vitiligo from the perspectives of patients and healthcare professionals (HCPs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The survey recruited adults (\u2265 18\u2005years) diagnosed with vitiligo and HCPs treating patients with vitiligo via an online panel in 17\u00a0countries. Patients were queried regarding clinical characteristics and vitiligo treatment. HCPs were queried regarding diagnosis and management of patients with vitiligo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Included in the analysis were 3541 patients and 1203 HCPs. Nearly half (45.2%)\u00a0of the patients had &amp;gt; 5% affected body surface area; 57.1% reported family history. Patients obtained formal diagnosis after a mean (SD) of 2.4 (4.1) years; 44.9% reported previous misdiagnosis. Many patients (56.7%) reported being told that vitiligo could not be treated; 53.9% of HCPs believed patients who never treated their vitiligo had been told that vitiligo could not be treated. One-quarter of HCPs (26.3%) did not believe that an effective therapy for vitiligo exists; 44.6% of patients reported giving up on finding an effective therapy. Top treatment goals for patients and HCPs, respectively, were reduction or cessation of spread (24.7% and 18.5%) and repigmentation (22.5% and 37.2%). Patient perception of effective care was similar for treatment by dermatologists (66.9%) and primary care HCPs (67.0%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with vitiligo and HCPs reported similar treatment goals and expressed frustration with the lack of effective therapies. Patients reported high rates of initial misdiagnosis; many ceased seeking healthcare because they perceived that vitiligo could not be treated. The findings highlight the need for earlier diagnosis and improved disease management for vitiligo.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad245","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T13:22:22Z","timestamp":1690377742000},"page":"569-577","source":"Crossref","is-referenced-by-count":38,"title":["Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study"],"prefix":"10.1093","volume":"189","author":[{"given":"Iltefat H","family":"Hamzavi","sequence":"first","affiliation":[{"name":"Henry Ford Medical Center , Detroit, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Bibeau","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Grimes","sequence":"additional","affiliation":[{"name":"Vitiligo & Pigmentation Institute of Southern California , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E","family":"Harris","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , Worcester, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[{"name":"Ghent University Hospital , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Parsad","sequence":"additional","affiliation":[{"name":"Post Graduate Institute of Medical Education and Research , Chandigarh , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Tulpule","sequence":"additional","affiliation":[{"name":"Shweta Association , Pune , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Gardner","sequence":"additional","affiliation":[{"name":"Vitiligo Support International , Lynchburg, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Valle","sequence":"additional","affiliation":[{"name":"Vitiligo Research Foundation , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaone","family":"Tlhong Matewa","sequence":"additional","affiliation":[{"name":"Beyond Vitiligo , Johannesburg , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"LaFiura","sequence":"additional","affiliation":[{"name":"Envision Health Partners LLC , Riverside, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Ren","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"2023102707074982900_ljad245-B1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"2023102707074982900_ljad245-B2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"2023102707074982900_ljad245-B3","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan, and the USA","volume":"36","author":"Bibeau","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023102707074982900_ljad245-B4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","article-title":"Vitiligo is not a cosmetic disease","volume":"73","author":"Ezzedine","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2023102707074982900_ljad245-B5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000354607","article-title":"Comorbidities associated with vitiligo: a ten-year retrospective study","volume":"227","author":"Sheth","year":"2013","journal-title":"Dermatology"},{"key":"2023102707074982900_ljad245-B6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","article-title":"Association between vitiligo extent and distribution and quality-of-life impairment","volume":"149","author":"Silverberg","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2023102707074982900_ljad245-B7","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaad.2019.07.036","article-title":"Comorbid diseases of vitiligo: a 10-year cross-sectional retrospective study of an urban US population","volume":"82","author":"Hadi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023102707074982900_ljad245-B8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjd.15199","article-title":"Vitiligo and depression: a systematic review and meta-analysis of observational studies","volume":"177","author":"Lai","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023102707074982900_ljad245-B9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/jdv.14739","article-title":"The prevalence and odds of depression in patients with vitiligo: a meta-analysis","volume":"32","author":"Wang","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023102707074982900_ljad245-B10","first-page":"6663646","article-title":"Meta-analytic review of high anxiety comorbidity among patients with vitiligo","volume":"2021","author":"Liu","year":"2021","journal-title":"Biomed Res Int"},{"key":"2023102707074982900_ljad245-B11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023102707074982900_ljad245-B12","doi-asserted-by":"crossref","first-page":"e0241445","DOI":"10.1371\/journal.pone.0241445","article-title":"Vitiligo and anxiety: a systematic review and meta-analysis","volume":"15","author":"Kussainova","year":"2020","journal-title":"PLoS One"},{"key":"2023102707074982900_ljad245-B13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jaad.2020.09.088","article-title":"Beyond quality of life: a call for patients\u2019 own willingness to pay in chronic skin disease to assess psychosocial burden \u2013 a multicenter, cross-sectional, prospective survey","volume":"85","author":"Bae","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023102707074982900_ljad245-B14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/1346-8138.15743","article-title":"Vitiligo: a focus on pathogenesis and its therapeutic implications","volume":"48","author":"Bergqvist","year":"2021","journal-title":"J Dermatol"},{"key":"2023102707074982900_ljad245-B15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000275657","article-title":"Clinical features and treatment outcomes of vitiligo from the patients\u2019 perspective: results of a national survey in Germany","volume":"220","author":"Radtke","year":"2010","journal-title":"Dermatology"},{"key":"2023102707074982900_ljad245-B16","doi-asserted-by":"crossref","first-page":"e018652","DOI":"10.1136\/bmjopen-2017-018652","article-title":"Views and experiences of seeking information and help for vitiligo: a qualitative study of written accounts","volume":"8","author":"Teasdale","year":"2018","journal-title":"BMJ Open"},{"key":"2023102707074982900_ljad245-B17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jdv.16927","article-title":"Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo","volume":"35","author":"Narayan","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023102707074982900_ljad245-B18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/bjd.20137","article-title":"Development of a shared decision-making tool in vitiligo: an international study","volume":"185","author":"Shourick","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023102707074982900_ljad245-B19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaad.2016.09.034","article-title":"Development and validation of a patient-reported outcome measure in vitiligo: the Self Assessment Vitiligo Extent Score (SA-VES)","volume":"76","author":"van Geel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023102707074982900_ljad245-B20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jaad.2021.02.083","article-title":"Factors associated with perceived stress in patients with vitiligo in the ComPaRe e-cohort","volume":"86","author":"Condamina","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023102707074982900_ljad245-B21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1468-3083.2011.04131.x","article-title":"Differences between familial and sporadic cases of vitiligo","volume":"26","author":"Karelson","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023102707074982900_ljad245-B22","first-page":"981","article-title":"Genetic epidemiology of vitiligo: multilocus recessivity cross-validated","volume":"55","author":"Nath","year":"1994","journal-title":"Am J Hum Genet"},{"key":"2023102707074982900_ljad245-B23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/hmg\/ddaa005","article-title":"Deep genotype imputation captures virtually all heritability of autoimmune vitiligo","volume":"29","author":"Roberts","year":"2020","journal-title":"Hum Mol Genet"},{"key":"2023102707074982900_ljad245-B24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4103\/0378-6323.116737","article-title":"The psychosocial impact of vitiligo in Indian patients","volume":"79","author":"Pahwa","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2023102707074982900_ljad245-B25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2133.2010.09828.x","article-title":"Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo","volume":"163","author":"Thompson","year":"2010","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"2023102707074982900_ljad245-B26","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1111\/dth.12007","article-title":"Quality of life in vitiligo patients","volume":"25","author":"Teovska Mitrevska","year":"2012","journal-title":"Dermatol Ther"},{"key":"2023102707074982900_ljad245-B27","doi-asserted-by":"crossref","first-page":"e57-8","DOI":"10.1111\/bjd.15881","article-title":"Are vitiligo treatments cost-effective? A systematic review","volume":"178","author":"McManus","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023102707074982900_ljad245-B28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.19554","article-title":"An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo trial)","volume":"184","author":"Sach","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023102707074982900_ljad245-B29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/bjd.14283","article-title":"Cessation of spread as a treatment objective in vitiligo: perception from the patients\u2019 point of view","volume":"174","author":"van Geel","year":"2016","journal-title":"Br J Dermatol"},{"key":"2023102707074982900_ljad245-B30","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.17013","article-title":"International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation","volume":"180","author":"Eleftheriadou","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023102707074982900_ljad245-B31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/pcmr.12354","article-title":"Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus","volume":"28","author":"Eleftheriadou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"2023102707074982900_ljad245-B32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2011.10311.x","article-title":"Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients","volume":"165","author":"Ezzedine","year":"2011","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad245\/51230726\/ljad245.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/5\/569\/52625518\/ljad245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/5\/569\/52625518\/ljad245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:08:58Z","timestamp":1698390538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/5\/569\/7231249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,26]]},"published-print":{"date-parts":[[2023,10,25]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad245","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,7,26]]}}}